<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87747">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962792</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1119-CA</org_study_id>
    <secondary_id>PCI-32765 [Sponsor]</secondary_id>
    <nct_id>NCT01962792</nct_id>
  </id_info>
  <brief_title>Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma</brief_title>
  <official_title>A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 will be an open-label study. The dose escalation portion of the study is designed to
      establish the MTD of ibrutinib in combination with carfilzomib with or without
      dexamethasone.

      Phase 2b will be an open-label, multicenter study designed to evaluate the overall response
      rate when ibrutinib is administered in combination with carfilzomib and dexamethasone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other
      than T cells and is necessary for downstream signal transduction from various hematopoietic
      receptors including the B cell receptor as well as some Fc, chemokine, and adhesion
      receptors, and is crucial for both B cell development and osteoclastogenesis. Although
      down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from
      many myeloma patients and some cell lines. PCI-32765 is a potent and specific inhibitor of
      Btk currently in Phase 2 and 3 clinical trials. The current study is designed and intended
      to determine the safety and efficacy of PCI-32765 in combination with carfilzomib
      (Kyprolis™) with and without dexamethasone in subjects with relapsed or relapsed and
      refractory multiple myeloma (MM).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the maximum tolerated dose (MTD) of ibrutinib in combination with carfilzomib with and without dexamethasone and the recommended phase 2 dose.
To describe the toxicities associated with the combination of ibrutinib and carfilzomib with and without dexamethasone in subjects with relapsed or relapsed and refractory multiple myeloma (MM).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2b</measure>
    <time_frame>1 year</time_frame>
    <description>To evaluate the overall response (ORR) of ibrutinib in combination with carfilzomib and dexamethasone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1</measure>
    <time_frame>1 year</time_frame>
    <description>Overall response rate (ORR).
Duration of Response (DOR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2b</measure>
    <time_frame>1 year</time_frame>
    <description>PFS rates at landmark points from start of treatment.
DOR.
Overall survival (OS).
Time to progression (TTP).
To evaluate the safety and tolerability of ibrutinib in combination with carfilzomib and dexamethasone.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">127</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Phase 1 - Dose Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO + Carfilzomib IV + Dexamethasone PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2b - Main Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO + Carfilzomib IV + Dexamethasone PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2b - Sub-study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib PO + Carfilzomib IV + Dexamethasone PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>Phase 1 - Dose Finding</arm_group_label>
    <arm_group_label>Phase 2b - Main Study</arm_group_label>
    <arm_group_label>Phase 2b - Sub-study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <arm_group_label>Phase 1 - Dose Finding</arm_group_label>
    <arm_group_label>Phase 2b - Main Study</arm_group_label>
    <arm_group_label>Phase 2b - Sub-study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Phase 1 - Dose Finding</arm_group_label>
    <arm_group_label>Phase 2b - Main Study</arm_group_label>
    <arm_group_label>Phase 2b - Sub-study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Measurable disease of MM as defined by at least ONE of the following:

               1. Serum monoclonal protein (SPEP) ≥1 g/dL

               2. Urine M-protein ≥200 mg/24 hrs

               3. Serum free light chain (SFLC): involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal
                  kappa to lambda serum free light chain ratio

          -  Relapsed or relapsed and refractory MM after receiving at least 2 previous therapies,
             including an immunomodulator and bortezomib and had either no response or documented
             disease progression (according to IMWG criteria) to the most recent treatment regimen

          -  Adequate hematologic, hepatic, and renal function

          -  ECOG performance status of 0-2

        Inclusion Criteria for Phase 2 Sub-study Cohort:

          -  Must meet all inclusion criteria defined in main study and in addition the following
             criteria must be met:

          -  Subject must have received a regimen containing carfilzomib in combination with
             dexamethasone as their most recent line of therapy and have:

               1. Achieved less than a partial response (&lt;PR) following at least 4 cycles and are
                  without evidence of progression disease (PD).

                  OR

               2. Disease progression following an initial confirmed response of MR or better to
                  the combination (according to IMWG response criteria).

        Exclusion Criteria:

          -  Subject must not have primary refractory disease

          -  Plasma cell leukemia, primary amyloidosis or POEMS syndrome

          -  Unable to swallow capsules or disease significantly affecting gastrointestinal
             function

          -  Requires anti-coagulation with warfarin or a vitamin K antagonist

          -  Requires treatment with strong CYP3A inhibitors

        Exclusion Criteria for Phase 2 Sub-study Cohort:

          -  Must not meet any exclusion criteria defined in main study except for exclusion
             criteria &quot;Subject must not have primary refractory disease&quot; which is related to prior
             carfilzomib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lipo Chang</last_name>
    <phone>408-215-3437</phone>
    <email>lchang@pcyc.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>QC H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 6, 2016</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PCI-32765</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed Refractory Multiple Myeloma</keyword>
  <keyword>Bruton's Tyrosine Kinase</keyword>
  <keyword>Carfilzomib</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Ibrutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
